Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Rhea-AI Summary

Crescita Therapeutics announced the results from its Annual General and Special Meeting of Shareholders held on June 5, 2024, in Laval, Quebec. Key outcomes included the election of directors with strong support ranging from 98.3% to 99.9% approval. Daniel N. Chicoine, Anthony E. Dobranowski, John C. London, Deborah Shannon-Trudeau, and Serge Verreault were elected as directors. Ernst & Young LLP was reappointed as the external auditor with 98.0% approval. The company's Share Incentive Plan was also approved with 98.9% votes in favor.

Positive

• Election of directors received strong support, ranging from 98.3% to 99.9%.
• Reappointment of Ernst & Young LLP as the external auditor was approved with 98.0% votes.
• Share Incentive Plan received 98.9% approval, indicating strong shareholder support.

Negative

• None.

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel N. Chicoine	6,490,732	109,026	98.3%	1.7%
Anthony E. Dobranowski	6,508,888	90,870	98.6%	1.4%
John C. London	6,533,190	66,568	99.0%	1.0%
Deborah Shannon-Trudeau	6,541,297	58,461	99.1%	0.9%
Serge Verreault	6,590,211	9,547	99.9%	0.1%

Reappointment of External Auditors

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Ernst & Young LLP reappointed	7,212,551	148,556	98.0%	2.0%

Approval of the Continuation of Crescita’s Share Incentive Plan

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	AGAINST	FOR	AGAINST
Share Incentive Plan approved	6,526,477	73,281	98.9%	1.1%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606355142/en/

Linda Kisa, CPA, CA

Vice-President, Reporting and Corporate Affairs

Email: lkisa@crescitatx.com

Source: Crescita Therapeutics

FAQ

What were the results of Crescita Therapeutics' 2024 Annual Meeting for the election of directors?

The directors received a high approval rate, with votes ranging from 98.3% to 99.9%.

Was Ernst & Young LLP reappointed as Crescita Therapeutics' auditor in 2024?

Yes, Ernst & Young LLP was reappointed with 98.0% of votes in favor.

Did Crescita Therapeutics' Share Incentive Plan get approved in 2024?

Yes, the Share Incentive Plan was approved with 98.9% of the votes.